Christopher J. Molloy, Ph.D., R.Ph., Senior Vice President

Christopher J. Molloy, Ph.D., R.Ph., led the Rutgers-UMDNJ integration and became senior vice president for research and economic development in November 2013. His responsibilities include oversight and strategic planning for the university’s nearly $660 million in annual research expenditures and management of the many institutional offices and resources that support Rutgers’ research and economic development activities.

Under Molloy’s leadership, the Office of Research and Economic Development is expanding its commercialization of research through patents, startups and the transfer of technology to industry, maximizing the university’s ability to conduct translational research in the life sciences and other critical research and development activities. It also is promoting more public-private partnerships to bring new jobs to New Jersey. And the office is providing enhanced services to foster interdisciplinary collaborations, facilitate corporate contracts and support the faculty’s submission of grant proposals to governmental and private sponsors.

Molloy joined Rutgers in 2007 as dean of the Ernest Mario School of Pharmacy. In 2011, he was appointed interim provost for biomedical and health sciences and successfully managed the complex integration of Rutgers and most of the former UMDNJ. Molloy served as interim chancellor of Rutgers Biomedical and Health Sciences from July 2013 until joining ORED four months later.

He received his bachelor’s degree in pharmacy from Rutgers and his doctoral degree from the joint Rutgers Graduate School of Biomedical Sciences at Robert Wood Johnson Medical School/Graduate School–New Brunswick. He was a post-doctoral fellow at the National Cancer Institute. 

Molloy was named a Fellow of the American Association for the Advancement of Science (AAAS) in 2016.

Prior to joining Rutgers, Molloy held senior research and management positions at Johnson and Johnson Pharmaceutical Research and Development L.L.C., 3-Dimensional Pharmaceuticals Inc., and the Bristol-Myers Squibb Pharmaceutical Research Institute.

                      Watch Dr. Molloy on the WNET and NJTV program One on One